Ankyrons: The future of target-binding reagents beyond antibodies
Ankyrons™ are next-generation target binding reagents provided by ProImmune that overcome many of the current constraints of research antibodies. They are highly stable recombinant single-domain binders that can be directly labelled or detected via an epitope or biotin tag. Ankyrons can be engineered to combine them with further Ankyron or other domains much more easily than even recombinant Antibodies. Unlike Antibodies, Ankyrons are never made in animals and do not have isotypes or any species origin.
The Finance of Immunogenicity
Managing immunogenicity risk should be a core focus in drug development. ProImmune’s CEO Nik Schwabe explains why.
ProPresent® – ProImmune’s Antigen Presentation Assay
Dr Nikolai Schwabe introduces the ProPresent antigen presentation assay and some of its applications in the field of immunogenicity.
HLA Tissue Typing
Dr Briana Betz explains the importance of understanding the HLA types of your study cohort, and how ProImmune can help you.
Pro5® MHC Pentamers
Charlotte Thompson provides an overview of the Pro5 Pentamer technology and the benefits of using MHC pentamers to detect specific CD8 T Cell populations in your research.
ProImmune REVEAL and ProVE®
Dr Jeremy Fry provides a summary of ProImmune’s REVEAL and ProVE® service, the rapid epitope discovery system.
